Yazen closes oversubscribed €19.5M series A to accelerate growth
Yazen Health, the healthcare platform dedicated to combating obesity with modern weight loss medication and lifestyle changes, announced today the successful closing of an oversubscribed €19.5 million Series A funding round. With this funding, the company strengthens its position as a pioneer in obesity treatment and sets its sights on international expansion.
The funding round was co-led by Evli Growth Partners (Finland) and Helsana HealthInvest (Switzerland) with participation from Almaz Capital (Germany) and Yabeo (Germany).
Yazen is also supported in this funding round by existing Swedish investors Luminar Ventures and Aggregate Media.
At the forefront of tackling the global obesity crisis
Obesity is one of the world’s most widespread health problems, and Yazen has developed a holistic model that can make a long-lasting impact. By combining modern weight loss medication with a multidisciplinary team of doctors, coaches, dietitians, psychologists and physiotherapists, Yazen has helped over 20,000 patients in Sweden, showing an impressive 70% retention rate after one year.
The company is already profitable in the Swedish market and the new financing will be used to further scale the business internationally, including Spain, Norway, and the Netherlands, where they already have a strong foothold, while also strengthening their pilot markets in the UK and Germany. Yazen has ambitious plans to triple growth for the next 2-3 years, focusing on enhancing its offering, strengthening the organisation, and expanding into additional countries – all with the aim of helping the world become healthier.
Developing services and the app to benefit patients
The investment will also enable further development of Yazen's app and its holistic care service, designed to better support patients on their journey toward healthier lives. Yazen provides a complete care model where patients receive support from a dedicated team of doctors, YazenCoaches, psychologists, dietitians, and physiotherapists – delivering a comprehensive solution reflected in excellent customer reviews and engagement. It’s not just the medication that makes the difference; it’s the collaborative approach from the entire Yazen team that creates magic for patients.
New chairman of the board from Rovio
As a result of the funding round, Yazen welcomes Mikael Hed, founding partner at Evli Growth Partners and former CEO of Rovio (creators of Angry Birds), as the new Chairman of the Board. His background in building and scaling an international brand will be an invaluable asset to Yazen as it enters its next phase of growth.
“We are extremely proud of what we’ve achieved so far and the strong growth we’ve seen in Sweden. This funding gives us the opportunity to continue our mission to defeat obesity on a global scale. With Mikael Hed as our new Chairman and the support of our new investors, we are better positioned than ever to make a difference,” said Fredrik Meurling, CEO and Founder of Yazen.
“Yazen’s comprehensive offering has quickly demonstrated an impressive track record. I look forward to leading the board’s work and, together with both existing and new investors, continuing Yazen’s international expansion,” said Mikael Hed, Growth Partner at Evli Growth Partners.
For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.